In vitro anticancer evaluation of Visha Bilvadi Agada against HepG2 hepatocellular carcinoma cell line using sulforhodamine B assay
Ayush Journal of Integrative Oncology · 2026-04 · 3 (2) · 90-95
DOI: 10.4103/ajio.ajio_13_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ayush Journal of Integrative Oncology, online erschienen am 14.07.2026. Verfasst von Bhaktiben Dipakkumar Kapdi und 3 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Liver cancer remains a major global health concern, necessitating exploration of alternative therapeutic agents. Visha Bilvadi Agada , a classical Ayurvedic polyherbal formulation containing sixteen herbal ingredients, is enriched with phytoconstituents possessing reported anticancer, antioxidant, anti-inflammatory, and radioprotective activities, suggesting its potential role in hepatocellular carcinoma management. Therefore, the present study was undertaken to evaluate the anticancer potential of Visha Bilvadi Agada against the HepG2 hepatic cancer cell line using the sulforhodamine B (SRB) assay. Materials and Methods: HepG2 cells were cultured in Dulbecco’s Modified Eagle Medium high glucose supplemented with 10% fetal bovine serum and maintained at 37°C in 5% CO 2 . The cells were seeded at a density of 15,000 cells/well in 96-well plates and treated with serial concentrations (100–1000 μg/mL) of the test sample for 24 h. The cell viability was assessed by the SRB assay, and percentage inhibition was calculated relative to untreated controls. Doxorubicin served as the standard drug.
Results
Visha Bilvadi Agada demonstrated dose-dependent cytotoxicity. Maximum inhibition of 79.9% was observed at 1000μg/mL, while minimum inhibition of 19.0% was seen at 100 μg/mL. The IC 50 value was calculated as 513 μg/mL. In contrast, doxorubicin exhibited 75% inhibition at 2.5 μM with significantly higher potency (half maximal inhibitory concentration: 0.00091 μM).
Conclusion
Visha Bilvadi Agada exhibits moderate in vitro antiproliferative activity against HepG2 cells.
Zitieren
APA
Kapdi, B. D., Chauhan, A., Solanki, V. R., & Muzammel, M. (2026). In vitro anticancer evaluation of Visha Bilvadi Agada against HepG2 hepatocellular carcinoma cell line using sulforhodamine B assay. Ayush Journal of Integrative Oncology, 3(2), 90-95. https://doi.org/10.4103/ajio.ajio_13_26
Vancouver
Kapdi BD, Chauhan A, Solanki VR, Muzammel M. In vitro anticancer evaluation of Visha Bilvadi Agada against HepG2 hepatocellular carcinoma cell line using sulforhodamine B assay. Ayush Journal of Integrative Oncology. 2026;3(2):90-95. doi:10.4103/ajio.ajio_13_26
BibTeX
@article{Kapdi2026,
author = {Kapdi, Bhaktiben Dipakkumar and Chauhan, Aniswa and Solanki, Varsha R. and Muzammel, Mohamed},
title = {In vitro anticancer evaluation of Visha Bilvadi Agada against HepG2 hepatocellular carcinoma cell line using sulforhodamine B assay},
journal = {Ayush Journal of Integrative Oncology},
year = {2026},
volume = {3},
number = {2},
pages = {90--95},
doi = {10.4103/ajio.ajio_13_26}
}
EUVIMED